RESUMEN
Thrombotic risk should always be assessed in the various clinical scenarios of patients with cancer. Thromboprophylaxis with low-molecular-weight heparin is recommended above other anticoagulants for most patients with cancer who are hospitalised. However, the safety of primary thromboprophylaxis in this context is unknown; however, thromboprophylaxis can be completed with mechanical methods. Thromboprophylaxis in outpatients who are treated with chemotherapy is not indicated, except for outpatients who have other factors that determine a high thrombotic risk. In these cases, prophylaxis such as apixaban, rivaroxaban and low-molecular-weight heparin may be employed, provided there are no significant risk factors for bleeding or drug interactions. In patients undergoing oncologic surgery, thromboprophylaxis should be started before the surgery, continuing for at least 7 to 10 days and, in cases of major surgery, even up to 4 weeks. Drug prophylaxis is not routinely recommended to prevent upper extremity thrombosis in patients who carry central venous catheters.
RESUMEN
The traditional Castleman's Disease is characterized by the presence of a single tumor constituted by hyperplasic lymphoid tissue. It is usually asymptomatic and has a good prognosis. More recently, another disease which is histologically undistinguishable has been described. However, it courses with polyadenopathic signs, consumptive syndrome, anemia, hypergammaglobulemia and fever and has been called multicentric Castleman's Disease. A comprehensive review of national and international literature is included.